Kendall Morrison

University of Santa Monica — United States

Medicine · Health Sciences

16h-index1.5kcitations115works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(42), Monoclonal and Polyclonal Antibodies Research(20), Renal and related cancers(19), HER2/EGFR in Cancer Research(13), Glycosylation and Glycoproteins Research(10)

Publications115 total

First estimation of the clinical utility of boronotyrosine as a boron delivery compound for boron neutron capture therapy in head and neck cancer
Applied Radiation and Isotopes·2026
BORON NEUTRON CAPTURE THERAPY AND THE EXPRESSION OF LAT1, GLUT1, GALECTINS AND DNA REPAIR MACHINERY IN HAMSTER ORAL TUMORS
International Journal of Particle Therapy·2025Open Access
BORONTYROSINE BIODISTRIBUTION AND MICRODISTRIBUTION STUDIES FOR BORON NEUTRON CAPTURE THERAPY: PRELIMINARY STUDIES IN AN EXPERIMENTAL ORAL CANCER MODEL
International Journal of Particle Therapy·2025Open Access
AB012. Tissue uptake of novel boron neutron capture therapy compounds in a mouse model, with pharmacokinetic and dosimetric extrapolation to human treatment
Therapeutic Radiology and Oncology·2025Open Access
2535eP Incidence of incidental primary lung malignancies vs. solitary prostate cancer lung metastasis detected on PSMA-PET CT scans for prostate cancer staging and surveillance
Annals of Oncology·2025
Exploratory Rat Toxicology and Efficacy of the Boron Neutron Capture Therapy Drug Boronotyrosine in a Mouse Model of Head and Neck Cancer
International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited
Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose
Clinical and Translational Radiation Oncology·2025Open Access
First Estimation of the Clinical Utility of Boronotyrosine as a Boron Delivery Compound for Boron Neutron Capture Therapy in Head and Neck Cancer
SSRN Electronic Journal·2025· 1 citedOpen Access
First estimation of the clinical utility of boronotyrosine as a boron delivery compound for boron neutron capture therapy in head and neck cancer
SSRN Electronic Journal·2025Open Access
1485: Development of GLUT-1 targeted boron carriers for Boron Neutron Capture Therapy (BNCT)
Radiotherapy and Oncology·2024
Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field
Journal of Medicinal Chemistry·2023· 25 cited
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Pia M. Challita-Eid(28), Zili An(28), Arthur Raitano(28), David R. Stover(28), Linnette Capo(26), Héctor Aviña(26), Fernando Doñate(25), Daniel S. Pereira(24), Ingrid B.J. Joseph(24), Sher Karki(21), Daulet Satpayev(18), Yuriy Shostak(18), Rossana Nadell(18), Wendy Liu(18), Jimmy Ou(18), Karen Morrison(18), Ryuichi Moriya(15), Faisal Malik(15), Peng Yang(14), John Atkinson(14)